Explore Livagen dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Livagen is a short-chain peptide bioregulator from the Khavinson family, derived from the sequence Lys-Glu-Asp-Ala and studied for its reported effects on hepatic cell function and chromatin decondensation in lymphocytes from elderly donors. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Livagen.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson as part of the broader Khavinson short-peptide bioregulator program. Within that framework — which proposes that very short organ-specific oligopeptides exert tissue-targeted epigenetic regulation by binding gene-promoter regions and modulating transcription in their tissue of origin — Livagen is positioned as a hepatic bioregulator, conceptually downstream of the multi-peptide liver extract Cytogen from which the synthetic sequence was derived.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala) from the Khavinson short-peptide bioregulator program, sourced for liver and immune-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and its sequence differs from Cardiogen by a single residue.
In the Khavinson framework, Livagen is proposed to act through direct binding to gene-promoter DNA in hepatocytes and peripheral lymphocytes, selectively modulating transcription of genes involved in hepatic detoxification pathways, antioxidant defense, and chromatin remodelling. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian single-site studies have reported Livagen as an adjunct in chronic hepatitis, age-related hepatic decline, and immune-modulation contexts, with reported improvements in liver-function tests and lymphocyte chromatin-condensation markers versus standard care. These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Livagen has a reported half-life of ~few hours (bioregulator estimate), and the dose intervals researchers model most often fall around once daily (in courses). Short plasma exposure with daily dosing means no systemic buildup; like other Khavinson bioregulators it is run in short courses and its effects are thought to outlast the plasma half-life. It is catalogued under Anti-Aging Peptides on WPA.
37 Livagen reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (22 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (31 sessions). The most common dosing frequency is daily (7x/week) (2 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.